Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue SUPPL. 2, 2003, Pages 13-16

  Hochberg, M C ^a,b   Tracy, J K ^a   Hawkins Holt, M ^a   Flores, R H ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MSTF 8 34 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; DATA ANALYSIS; DEMOGRAPHY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; HEALTH CARE ORGANIZATION; HUMAN; MEASUREMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142156483     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
2. Rasch EK, Hirsch R, Faulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917-26.
3. ACR. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
4. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
5. Williams HJ, Wilkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Efficacy of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
6. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997;40:984-5.
7. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
8. Osman A, Mulherin D. Is parenteral methotrexate worth trying? Ann Rheum Dis 2001;60:432.
9. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-19.
10. Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: a systematic review of randomized placebo-controlled trials in patients with active rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 2001;60(suppl III):iii51-4.
11. Rau R. Adalimumab (a fully human anti-tumor necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002;61(uppl II):ii70-3.
12. Abbott Laboratories. Humira™ (adalimumab). Product information. North Chicago, IL, USA: Abbott Laboratories, December 2002.
13. Boers M, Tugwell P, Felson DT, van Riel P, Kirwan J, Edmonds J, et al. World Health Organization and International League for Associations of Rheumatology core endpoints for symptom modifying antirheumatoid drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;21(suppl 41):86-9.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
15. Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
16. Pagano M, Gauvreau K. Principles of biostatistics. Belmont, CA: Duxbury Press, 1993:341-52.
17. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
18. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472-6.
19. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
20. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
21. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
22. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully humanized anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35-45.
23. Keystone E, Kavanaugh AF, Sharp J, Hua Y, Teoh L, Firschkoff S, et al. Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46(suppl): S205 (abstract 468).
24. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Biljsma JWJ, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002;61(suppl II):ii2-7.
25. McAlister FA, Laupacis A, Wells GA, Sackett DL, for the Evidence-Based Medicine Working Group. Users' guide to the medical literature XIX. Applying clinical trial results. B. guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7.
26. Fleischmann RM. Examining the efficacy of biologic therapy: are there real differences? J Rheumatol 2002;29(suppl 65):27-32.
27. Dayer J-M, Bresnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:574-8.
28. Cush JJ, Matteson E. FDA Advisory Committee reviews safety of TNF inhibitors. American College of Rheumatology Hotline, September 2001 (available at http://www.rheumatology.org/research/hotline/ 0901tnf.html).
29. Cush JJ, Kavanaugh A. FDA Meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. American College of Rheumatology Hotline, March 2003 (available at http://www.rheumatology.org/ research/hotline/0303TNFL. htm).